Company Overview - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses [3] - The company's lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials [3] - CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, California [3] Clinical Trials and Presentations - A late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool has been accepted for the ACG 2024 Annual Scientific Meeting, scheduled for October 28-30 in Philadelphia [1] - The presentation will focus on the CARPO clinical trial, which studies acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS) [1][2] - CalciMedica is currently conducting several clinical trials, including a Phase 2b trial (CARPO) for AP with SIRS, a Phase 2 trial (KOURAGE) for acute kidney injury (AKI) with associated acute hypoxic respiratory failure (AHRF), and a Phase 1/2 trial (CRSPA) for acute intestinal pseudo-obstruction (AIPT) [3]
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting